全文获取类型
收费全文 | 1435756篇 |
免费 | 118470篇 |
国内免费 | 5510篇 |
专业分类
耳鼻咽喉 | 18673篇 |
儿科学 | 46873篇 |
妇产科学 | 41370篇 |
基础医学 | 204018篇 |
口腔科学 | 38204篇 |
临床医学 | 129708篇 |
内科学 | 288022篇 |
皮肤病学 | 33691篇 |
神经病学 | 118277篇 |
特种医学 | 54897篇 |
外国民族医学 | 480篇 |
外科学 | 213021篇 |
综合类 | 37702篇 |
现状与发展 | 10篇 |
一般理论 | 493篇 |
预防医学 | 111923篇 |
眼科学 | 32306篇 |
药学 | 101617篇 |
20篇 | |
中国医学 | 5107篇 |
肿瘤学 | 83324篇 |
出版年
2021年 | 12345篇 |
2019年 | 12673篇 |
2018年 | 17616篇 |
2017年 | 13713篇 |
2016年 | 15213篇 |
2015年 | 17331篇 |
2014年 | 24298篇 |
2013年 | 34966篇 |
2012年 | 47638篇 |
2011年 | 50311篇 |
2010年 | 29660篇 |
2009年 | 28236篇 |
2008年 | 45873篇 |
2007年 | 48326篇 |
2006年 | 48798篇 |
2005年 | 47250篇 |
2004年 | 44707篇 |
2003年 | 42620篇 |
2002年 | 40975篇 |
2001年 | 73608篇 |
2000年 | 75068篇 |
1999年 | 62112篇 |
1998年 | 17376篇 |
1997年 | 15778篇 |
1996年 | 15842篇 |
1995年 | 15066篇 |
1994年 | 13631篇 |
1993年 | 12753篇 |
1992年 | 46006篇 |
1991年 | 43643篇 |
1990年 | 41614篇 |
1989年 | 39667篇 |
1988年 | 36297篇 |
1987年 | 35424篇 |
1986年 | 32924篇 |
1985年 | 31330篇 |
1984年 | 23842篇 |
1983年 | 20053篇 |
1982年 | 12212篇 |
1981年 | 10791篇 |
1979年 | 20709篇 |
1978年 | 14578篇 |
1977年 | 12086篇 |
1976年 | 11367篇 |
1975年 | 11623篇 |
1974年 | 13991篇 |
1973年 | 13541篇 |
1972年 | 12635篇 |
1971年 | 11473篇 |
1970年 | 10913篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
81.
82.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献83.
Provocation of Atrial Fibrillation Triggers During Ablation: Does the Use of General Anesthesia Affect Inducibility?
下载免费PDF全文
![点击此处可从《Journal of cardiovascular electrophysiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
84.
85.
A case of bullous pemphigoid associated with psoriasis vulgaris showing Hailey–Hailey disease‐like histopathological changes in regenerated epidermis without genomic mutation in ATP2C1 or ATP2A2 gene
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
86.
观察电针对缺血性脑卒中大鼠记忆功能及脑内突触囊泡蛋白(synaptic vesicular protein,SYN)的影响,探讨其可能的作用机制。方法 选取90 只SD大鼠随机分为模型组、电针组、假手术组,每组各30只。线拴法制作急性大脑中动脉缺血大鼠模型。电针组取“百会”“水沟”“内关”“三阴交”穴位,应用“醒脑开窍”法进行电针,每天电针30 min,连续电针6 d休1 d,7 d为一个疗程,首次电针干预在造模成功24 h后进行。模型组和假手术组不进行电针干预。大鼠分别按7、14、21 d 3个亚组进行运动及记忆功能评分,TTC染色测定脑梗死体积、Western blot检测脑内SYN的蛋白表达。结果 电针组运动功能评分较模型组显著降低(P<0.01),电针组进入隐藏区潜伏期时间较模型组显著缩短(P<0.01),电针组脑梗死率较模型组显著缩小(P<0.01),SYN的蛋白表达电针组较模型组明显增强(P<0.01)。假手术组无神经功能缺损及脑梗死灶,SYN表达最弱。结论 电针干预能减小脑梗死体积,上调脑内SYN的表达,进而促进缺血性脑卒中大鼠的记忆及运动等神经功能的恢复。 相似文献
87.
C. Dessinioti C.C. Zouboulis V. Bettoli D. Rigopoulos 《Journal of the European Academy of Dermatology and Venereology》2020,34(10):2229-2240
Guidelines and consensus on the management of patients with acne aim to give evidence-based, expert-group recommendations. This review compares current guidelines and consensus articles to provide a compilation of recommendations on the treatment of acne with oral isotretinoin. Ten common, relevant, clinical questions are addressed, based on published recommendations, including the indications of isotretinoin, the proposed daily dose, the cumulative isotretinoin dose and the laboratory monitoring needed. Recommendations on special considerations are also addressed, including the timing of procedures and the question of an association of depression or inflammatory bowel disease with isotretinoin. A major limitation is the use of different classification systems for acne across guidelines. The recommended daily dose ranges from 0.3 to 0.5 mg/kg in the European guidelines to up to 1 mg/kg in the US guidelines. A specific duration of treatment of at least 6 months is only recommended in the European guidelines. All guidelines report the need of strict pregnancy prevention measures. The European, French and US guidelines recommend to monitor for symptoms of depression. Important clinical questions that are inconsistently addressed in guidelines include the age indication, the recommendation for a cumulative dose, the timing of procedures, the association of isotretinoin with IBD, the recommendation for preventing acne flares and for appropriate laboratory monitoring. These topics should be clearly included in the recommendations of guidelines as they are often raised in everyday clinical practice. 相似文献
88.
89.
90.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600